XML 172 R9.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Balance Sheet Components | 6 Months Ended
--- | ---
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Balance Sheet Components | Balance Sheet Components Property, Plant and Equipment, Net Property, plant and equipment, net consist of the following (in thousands):
| June 30, 2024 |  | December 31, 2023
Land | $ | 31,243 |  |  | $ | 31,243 |
Laboratory equipment | 3,615 |  |  | 8,291 |
Buildings | 102,433 |  |  | 102,433 |
Office and computer equipment | 621 |  |  | 831 |
Leasehold improvements | 154 |  |  | 1,424 |
Manufacturing equipment | 406 |  |  | 2,017 |
Total property, plant and equipment, gross | 138,472 |  |  | 146,239 |
Less: accumulated depreciation | (5,342) |  |  | (7,555) |
Total property, plant and equipment, net | $ | 133,130 |  |  | $ | 138,684 |
Depreciation expense was $1.0 million and $1.0 million for the three months ended June 30, 2024 and 2023, respectively, and was $2.0 million and $2.8 million for the six months ended June 30, 2024 and 2023, respectively, in the condensed consolidated statements of operations and comprehensive loss. The Company capitalized interest of nil and $1.3 million during the three months ended June 30, 2024 and 2023, respectively, while during the six months ended June 30, 2024 and 2023, the Company capitalized nil and $2.4 million, respectively, of interest related to qualifying expenditures for construction work-in-progress for its Tarzana manufacturing facility. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands):
| June 30, 2024 |  | December 31, 2023
Accrued compensation and benefits | $ | 1,998 |  |  | $ | 1,026 |
Accrued operational expenses | 1,179 |  |  | 1,412 |
Accrued restructuring costs | 3,211 |  |  | 3,136 |
Accrued research, development and clinical trial expenses | 872 |  |  | 1,833 |
Operating lease liabilities, current | 1,669 |  |  | 1,750 |
Other current liabilities | 143 |  |  | 190 |
Total accrued expenses and other current liabilities | $ | 9,072 |  |  | $ | 9,347 |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration